Module 7 Opioids

Question 1

analgesic

Answer 1

Having the ability to relieve pain (usually refers to a drug).

Question 2

analogs

Answer 2

Having a chemical structure similar to another compound but different in one or more components, often developed and distributed as a means of circumventing laws restricting manufacture/distribution of the drug for which it is an analog.

Question 3

buprenorphine

Answer 3

An opioid medication used in the treatment of opioid use disorder (partial mu-opioid receptor agonist).

Question 4

carfentanil (or carfentanyl)

Answer 4

An extremely powerful, addictive synthetic opioid originally intended for large animal veterinary practice.

Question 5

endogenous

Answer 5

Originating inside the body.

Question 6

exacerbated

Answer 6

Meaning that something is made worse.

Question 7

exogenous

Answer 7

Originating outside the body.

Question 8

fentanyl

Answer 8

An extremely powerful, addictive synthetic opioid, often mixed with other substances, with a strong presence in illicit drug trafficking but originally intended for prescription pain management in human and veterinary medicine.

Question 9

heroin

Answer 9

A powerful, addictive opioid derived from morphine (naturally derived from opium poppy), produced in various forms (e.g., white powder, brown powder, black tar) and having no recognized medical use in the U.S. (Schedule I drug by the DEA).

Question 10

medication assisted treatment (MAT)

Answer 10

Use of prescription medications under medical supervision to treat substance use disorders of various types and deter relapse through management of cravings and withdrawal symptoms and/or interrupting the substance-use reward system; recommended that behavioral interventions accompany MAT.

Question 11

methadone

Answer 11

A long-acting opioid used in treating opioid use disorder (originally developed as a strong pain reliever/analgesic narcotic) working as an opioid receptor agonist; because of its addictive potential, it remains a Schedule II drug by the DEA.

Question 12

methadone maintenance therapy (MMT)

Answer 12

An integrated treatment protocol for recovery from opioid use disorder, combining long-term prescribing of methadone in combination with behavioral counseling and other social services to support recovery.

Question 13

naloxone

Answer 13

An opioid antagonist drug with low addictive potential used both in the immediate reversal of opioid overdose (causing immediate withdrawal) and in longer-term medication assisted treatment of opioid use disorder.

Question 14

naltrexone

Answer 14

An opioid/opiate antagonist that blocks positive effects from using opioids or alcohol, decreasing the desire to use these substances in the future.

Question 15

narcotics

Answer 15

Drugs designed for pain management/relief; the term now commonly refers to illicitly used/trafficked opioids.

Question 16

neonatal withdrawal syndrome (NWS)

Answer 16

A cluster of symptoms frequently observed in newborn infants who have been prenatally exposed to opioids, triggered by separation from the source of these substances via the placenta causing the infant to experience substance withdrawal.

Question 17

opiates

Answer 17

Psychoactive substances that interact with opioid receptors and are produced from natural sources (e.g., opium, morphine, codeine); opiates are now considered to fall under the broader opioid category.

Question 18

opioids

Answer 18

Psychoactive substances that interact with opioid receptors; may be “natural,” synthetic, or partially/semi-synthetic in origin.

Question 19

opioid agonist

Answer 19

A substance or drug that activates opioid receptors resulting in some (partial agonist) or all (full agonist) opioid effects—heroin, methadone, morphine are full opioid agonists and buprenorphine is a partial agonist.

Question 20

opioid antagonist

Answer 20

A substance or drug that blocks opioid receptors thereby interfering with opioid effects—naloxone is an opioid antagonist.

Question 21

opioid use disorder (OUD)

Answer 21

A diagnostic label applied when 2 or more of 11 criteria listed in the DSM-5 are met within the same 12-month period, with the degree of severity determined by the total number of criteria met.